Post-Marketing Safety Data for Brexanolone (Zulresso)
In this postmarketing surveillance data analysis, excessive sedation and loss of consciousness when receiving brexanolone occurred at lower rates than previously reported in clinical trials.
Don’t Forget About Brexanolone’s Little Sister: Zuranolone
While we have been talking about using brexanolone, marketed by Sage Therapeutics as Zulresso, for the treatment of postpartum depression, an oral version of this novel antidepressant - SAGE 217 or zuranolone - has [...]
Zulresso: Hope and Lingering Questions
Publish date: September 10, 2019 By Lee S. Cohen, MD The last decade has brought increasing awareness of the need to effectively screen for postpartum depression, with a majority of states across the country now having [...]
Moving Forward with Brexanolone (Zulresso): Pilot Program at the Cleveland Clinic
It has been a few months since Zulresso (brexanolone), the new FDA-approved treatment for postpartum depression, has been available. At our clinic, we have had multiple queries regarding how to obtain treatment with Zulresso. One [...]
FDA is Expected to Approve Brexanolone for the Treatment of Postpartum Depression
In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of postpartum depression (PPD). Â SAGE-547, now called brexanolone, is an allosteric modulator of GABAA receptors. Â Since that time, Sage Therapeutics [...]
Oral Allopregnanolone Analogue for Postpartum Depression Treatment
In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of postpartum depression (PPD). Â SAGE-547, now called brexanolone, is a neurosteroid, an analogue of allopregnanolone and an allosteric modulator of [...]
FDA Supports Intravenous Brexanolone for Postpartum Depression
In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of postpartum depression (PPD). Â SAGE-547, now called brexanolone, is an allosteric modulator of GABAA receptors. Â Since that time, Sage Therapeutics [...]
Brexanolone for Postpartum Depression: More Data, But Still Some Questions
In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of severe postpartum depression (PPD). Â SAGE-547, now called brexanolone, is an allosteric modulator of GABA-A receptors. Â We saw the preliminary [...]
Brexanolone: A New Drug for Postpartum Depression
In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of severe postpartum depression (PPD). SAGE-547, now called brexanolone, is an allosteric modulator of GABAA receptors. This drug was initially [...]
New Study at the CWMH: Brexanolone (SAGE-547) for Postpartum Depression
In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of severe postpartum depression. Â SAGE-547, now called brexanolone, is a new type of antidepressant: a formulation of allopregnanolone, which is [...]